Drug makers and health insurers rose, but not as much as the broad market, as traders rotated into more economically sensitive areas. AbbVie rose after the drug maker boosted its earnings projection for the year and posted higher sales, thanks to continued strength with its rheumatoid-arthritis drug Humira. Pfizer ticked up after brokerage UBS said the drug giant is poised to improve its share performance, despite a "frustrating year." Pfizer's pipeline is "improving" and deal activity could "rejuvenate investor interest," the brokerage said, as reported earlier.

-Rob Curran, rob.curran@dowjones.com